PharmD Info

A forum for Indian Pharmacy Professionals

Important: Registered today to have the complete access on this forum --- Register Here
Its an open online platform to share and discuss clinical research and publication related topics to develop your skills and knowledge on various research methodologies and its related outcome measurements.Eg:Statistical Analysis,Study Designs and Journal Clubs.
Forum rules: Dear User, Kindly read our forum rules before you proceed with our PharmD Info, Your first 5 posts/topics requires moderator approval and this website is purely meant for educational and knowledge sharing purpose only so you should not make any topics/replies/messages which criticize, threaten or abuse any member, pharmacy governing bodies and organizations. Your post will be deleted automatically by our BB Pruning System if your topic is not viewed by members for more than 5 days. So, make sure that your topics and its related contents are unique and valuable. We expect you to be an active member of our forum to continue with your free membership.Kindly note that if a member received more than five warnings from moderator/members they will be blocked automatically by our Bulletin Board system.
  • User avatar
#2477
Indian Pharmacopoeia Commision (IPC), Ghaziabad recently released Pharmacovigilance Guidance Document for Marketing Authorization Holders of Pharmaceutical Products in October 2017. Marketing Authorization Holder (MAH) refers to Pharma company or Sponsor. This document provides Pharmacovigilance guidance for Marketing Authorization Holders of Pharmaceutical Products.

This document is effective from 01 Jan 2018.
The pharmacovigilance guidance document was developed by the National Coordination Centre of the Pharmacovigilance Programme of India (PvPI), Indian Pharmacopoeia Commission, in collaboration with the Central Drugs Standard Control Organization (CDSCO) and Ministry of Health & Family Welfare (MoHFW).

The objective of the guidance document is to ensure that a pharmacovigilance system is established at the Marketing Authorization Holder’s end in order mitigate risks associated with pharmaceutical products.

The guidance document also states that “it is required under rule to monitor adverse drug reactions/ complaints related to drugs marketed in the country by the MAH & submit it to the licensing authority / NCC PvPI” (Refer B.1.1)
Similar Topics
Topics Statistics Last post
0 Replies 
577 Views
by Admin
10 Sep 2018, 10:57
Pharmacovigilance openings -TCS
by Admin  - 27 Mar 2017, 12:54  - In: B Pharm Jobs
0 Replies 
1245 Views
by Admin
27 Mar 2017, 12:54
Openings for Pharmacovigilance - TCS
by Admin  - 03 May 2017, 14:16  - In: M Pharm Jobs
0 Replies 
1018 Views
by Admin
03 May 2017, 14:16
TCS Walk n Drive at HYD - Pharmacovigilance
by Admin  - 29 Nov 2017, 14:29  - In: B Pharm Jobs
0 Replies 
973 Views
by Admin
29 Nov 2017, 14:29
Pharmacovigilance job vacancies at Bangalore
by Admin  - 28 Apr 2017, 20:06  - In: M Pharm Jobs
0 Replies 
827 Views
by Admin
28 Apr 2017, 20:06

Tags

Indian Association of Colleges of Pharmacy. A/C N[…]

PharmD Info Online Group Discussion Disc[…]

PCI chalks out plans to allay concerns of educatio[…]

NAAC is in the process of developing a Manual for […]

WELCOME TO OUR E-LEARN COURSE WORK MODULES